Filter Results:
(4,661)
Show Results For
- All HBS Web
(4,661)
- People (16)
- News (1,868)
- Research (2,241)
- Events (2)
- Multimedia (220)
- Faculty Publications (1,827)
Show Results For
- All HBS Web
(4,661)
- People (16)
- News (1,868)
- Research (2,241)
- Events (2)
- Multimedia (220)
- Faculty Publications (1,827)
- 2006
- Case
In Reach Care of the Elderly: Moss Valley Medical Practice
By: Julie Battilana, A. M. Cagna and T. D'Aunno
- September 2006 (Revised December 2006)
- Case
Arizona Department of Public Health: The Challenges of Preparing for a Public Health Emergency
By: Lynda M. Applegate, Ajay Vinze, T. S. Raghu and Minu Ipe
In the post-9/11 era information technology enablement for emergency preparedness and response have taken on increased significance. Public health organizations like ADHS play a critical role in any statewide preparation for large scale emergencies. With issues like... View Details
Keywords: Problems and Challenges; Information Technology; Health Care and Treatment; Business Processes; Service Delivery; National Security; Health Industry; Health Industry; Arizona
Applegate, Lynda M., Ajay Vinze, T. S. Raghu, and Minu Ipe. "Arizona Department of Public Health: The Challenges of Preparing for a Public Health Emergency." Harvard Business School Case 807-016, September 2006. (Revised December 2006.)
- September 2014
- Supplement
Pfizer and AstraZeneca: Marketing an Acquisition (B)
By: John A. Quelch and James Weber
This (B) case provides a brief description of the outcome of the (A) case. View Details
Keywords: Health Care Policy; Pharmaceutical Sales; Mergers And Acquisitions; Marketing; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (B)." Harvard Business School Supplement 515-008, September 2014.
- January 2017 (Revised March 2021)
- Case
Fitbit
By: Regina E. Herzlinger, Christine Snively and Sarah Mehta
In 2019, Fitbit lost its leadership in the wearable sensor market to Apple and to cheaper alternatives.
Why did it lose its market position?
How will the proposed acquisition affect it and Google? View Details
Why did it lose its market position?
How will the proposed acquisition affect it and Google? View Details
- January 2019
- Teaching Note
Pricing PatientPing
By: Frank V. Cespedes
Teaching Note for HBS No. 818-017. PatientPing sells a software platform that allows health care providers to receive real-time notifications (“pings”) when one of their patients is admitted to or discharged from a health-care facility. The platform facilitates... View Details
- 28 Sep 2020
- News
Some Workers Face Looming Cutoffs in Health Insurance
- 01 Jul 2007
- News
Redefining Health Care: Creating Value-based Competition on Results
- 12 Jun 2020
- News
What Blockchain Could Mean for Your Health Data
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.
- August 14, 2020
- Comment
How Has COVID-19 Affected Health Insurance Offered by Small Businesses in the U.S.? Early Evidence from a Survey
By: Leemore S. Dafny, Yin Wei Soon, Zoë Cullen and Christopher T. Stanton
As the COVID-19 pandemic stretches toward its third quarter, loss of health insurance coverage has not figured prominently in the public debate. Data in this report demonstrate why that is, but also suggest that the apparent stability is fragile, with potentially... View Details
Keywords: Health Pandemics; Health Care and Treatment; Insurance; Small Business; Surveys; United States
Dafny, Leemore S., Yin Wei Soon, Zoë Cullen, and Christopher T. Stanton. "How Has COVID-19 Affected Health Insurance Offered by Small Businesses in the U.S.? Early Evidence from a Survey." NEJM Catalyst (August 14, 2020). (Commentary.)
- September 2014 (Revised February 2015)
- Case
Pfizer and AstraZeneca: Marketing an Acquisition (A)
By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
- October 2013 (Revised January 2015)
- Case
The Slingshot: Improving Water Access
By: John A. Quelch, Margaret L. Rodriguez and Carin-Isabel Knoop
In 2012, over 750 million people around the globe lacked access to safe drinking water. Dean Kamen, inventor of the Segway, sought to bring fresh water to poor and rural areas with the Slingshot, a water purification device. Kamen's challenge was to identify ways to... View Details
Keywords: Water; Public Health; Health Care; Slingshot; Dean Kamen; DEKA; Coca-Cola; Developing Markets; Freestyle; Safety; Natural Environment; Pollutants; Health; Distribution Channels; Developing Countries and Economies; Innovation and Invention; Africa; Latin America; South America; Asia
Quelch, John A., Margaret L. Rodriguez, and Carin-Isabel Knoop. "The Slingshot: Improving Water Access." Harvard Business School Case 514-007, October 2013. (Revised January 2015.)
- Research Summary
Overview
Phil's work aims to identify the drivers of performance for healthcare organizations and providers, and the mechanisms by which this performance can change over time. In complex healthcare settings, the optimal choice of treatment can be highly ambiguous. As a... View Details
- June 2024
- Article
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details
Shafrin, Jason, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington, and Richard Willke. "Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices." Forum of Health Economics and Policy 27, no. 1 (June 2024): 29–116.
- September 2023
- Teaching Note
Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment
Teaching Note for HBS Case No. 304-009. The case is part of the first module of the Innovating in Health Care course. Its purpose is to demonstrate how to evaluate the “do good” and do well” potential of a health care innovation. View Details
- August 2018
- Article
The Impact of the Entry of Biosimilars: Evidence from Europe
By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details
Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe
Scott Morton, Fiona M., Ariel Dora Stern, and Scott Stern. "The Impact of the Entry of Biosimilars: Evidence from Europe." Review of Industrial Organization 53, no. 1 (August 2018): 173–210.
- Article
Regulating Hospital Prices Based on Market Concentration Is Likely to Leave High-Price Hospitals Unaffected
By: Maximilian J. Pany, Michael E. Chernew and Leemore S. Dafny
Concern about high hospital prices for commercially insured patients has motivated several proposals to regulate these prices. Such proposals often limit regulations to highly concentrated hospital markets. Using a large sample of 2017 US commercial insurance claims,... View Details
Keywords: Health Care Providers; Hospitals; Insurance Market Regulation; Price Regulation; Markets; Health Care and Treatment; Cost; Quality; Insurance; Price; Governing Rules, Regulations, and Reforms
Pany, Maximilian J., Michael E. Chernew, and Leemore S. Dafny. "Regulating Hospital Prices Based on Market Concentration Is Likely to Leave High-Price Hospitals Unaffected." Health Affairs 40, no. 9 (September 2021): 1386–1394.